FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BLUM LEONARD M					2. Issuer Name and Ticker or Trading Symbol THERAVANCE INC [THRX]										heck all a	ship of Reportion applicable) rector ficer (give title	g Person(s) to Issuer 10% Owner Other (speci		wner
(Last) (First) (Middle) THERAVANCE, INC. 951 GATEWAY BOULEVARD					3. Date of Earliest Transaction (Month/Day/Year) 06/16/2014									A be			below)		
(Street) SOUTH FRANCI (City)	sco C.		94080 Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							ne) X Fo	l or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting orson					
		Tabl	e I - No	n-Deriv	ative	Sec	uritie	s Ac	quired	, Dis	posed o	f, oı	Bene	eficia	ally Ow	ned			
Date					h/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed Code (Instr. 5)		ies Acquired (A) Of (D) (Instr. 3, 4			d Sec Ber Ow	mount of urities eficially ned Following orted	6. Owner Form: D (D) or Ir (I) (Instr	Direct ndirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount		(A) or (D)	Price	Tra	nsaction(s) tr. 3 and 4)			(1130.4)
Common Stock 06/1				06/16/	2014			A		28,365(1)		A	\$	0 404,799		Г)		
		Та									sed of, onvertib				y Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	A. Deemed xecution Date, any Month/Day/Year) Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of		ount	8. Price of Derivative Security (Instr. 5)		Owi Fori Dire or Ii (I) (I	nership m: ect (D) ndirect nstr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

1. On February 11, 2011, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a six-year timeframe from 2011 through December 31, 2016 and continued employment. The award was amended in connection with the completion of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc. to convert a portion of the award (as then subject to performance conditions) to time-based vesting based on a factor that took into account the average price of both a share of Theravance common stock and an ordinary share of Theravance Biopharma for a period of ten days following the spin-off. The 28,365 shares will vest on June 2, 2015, subject to the reporting person's continued employment through such date.

Leonard M. Blum

06/18/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.